{
  "created_at": "Mon Jun 14 11:33:24 +0000 2021",
  "id_str": "1404378591035637762",
  "full_text": "Breaking News: Novavax’s Covid-19 vaccine demonstrated an overall efficacy of 90.4%, on par with the vaccines made by Pfizer-BioNTech and Moderna, in a new trial. But with the U.S. awash in other options, it might be needed more elsewhere. https://t.co/wyYGXxMlzG",
  "display_text_range": [
    0,
    263
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/wyYGXxMlzG",
        "expanded_url": "https://nyti.ms/3wnACs5",
        "display_url": "nyti.ms/3wnACs5",
        "indices": [
          240,
          263
        ]
      }
    ]
  },
  "user": {
    "name": "The New York Times",
    "screen_name": "nytimes",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/1098244578472280064/gjkVMelR_normal.png"
  },
  "retweet_count": 231,
  "favorite_count": 543,
  "possibly_sensitive": false,
  "original_created_at": "Mon Jun 14 10:02:02 +0000 2021",
  "localize": [
    {
      "locale": "ja",
      "full_text": "速報です。Novavax社のCovid-19ワクチンは、新しい試験で90.4%の総合的な有効性を示し、Pfizer-BioNTech社やModerna社のワクチンと同等の効果を示した。しかし、米国では他の選択肢が溢れているため、他の場所でもっと必要とされるかもしれない。https://t.co/wyYGXxMlzG"
    },
    {
      "locale": "zh",
      "full_text": "爆炸性新闻。Novavax公司的Covid-19疫苗在一项新的试验中显示出90.4%的总体疗效，与辉瑞-生物技术公司和Moderna公司的疫苗相当。但随着美国充斥着其他选择，其他地方可能更需要它。https://t.co/wyYGXxMlzG"
    },
    {
      "locale": "zh-Hant",
      "full_text": "爆炸性新聞。Novavax公司的Covid-19疫苗在一項新的試驗中顯示出90.4%的總體療效，與輝瑞-生物技術公司和Moderna公司的疫苗相當。但隨着美國充斥着其他選擇，其他地方可能更需要它。https://t.co/wyYGXxMlzG"
    }
  ]
}